Becton, Dickinson and Company (BD) reported fourth-quarter revenue up 5.6% to $5.3 billion, with adjusted earnings per share (EPS) up 27.3% to $4.15. Advanced Patient Monitoring, PureWick and biologic drug delivery grew by double digits. For the full year, revenue rose 3.9% to $19.5 billion and adjusted EPS rose 6.7% to $12.70. Free cash flow rose 42% to $2.9 billion; BD returned $3.6 billion to shareholders and paid down $2.4 billion of debt. For fiscal 2027, BD expects low-single-digit revenue growth and adjusted EPS of $13.10 to $13.30. The prior-year comparison for its Alaris infusion platform weighs on that outlook. BD's $19 billion US investment agreement could bring tariff relief, but the outlook includes no benefit from it.

Becton, Dickinson and Company (BD) reported fiscal year 2026 revenues of $19.5bn, up 4.9% year-over-year. Fourth-quarter revenue was $5.3bn, up 5.4%. Medical essentials was the top segment, rising 4.6% to about $3.9bn. Interventional grew 6.7% to about $3.8bn, and connected care reached about $3.5bn. BioPharma Systems was the smallest at $771m but grew fastest, at 17%. BD expects fiscal 2027 earnings of $13.10 to $13.30 per share. Its shares rose to $214.04 on November 5, giving it a market cap of around $58bn. Chief executive officer Tom Polen called the year "defining," as BD completed its shift to a more focused medtech company. In February 2026, it completed the $17.5bn spin-out and merger of its Biosciences and Diagnostic Solutions business with Waters Corporation's diagnostics unit.

BD (Becton, Dickinson and Company) reported fourth-quarter revenue of $5.3 billion, up 5.4% as reported and 5.6% at constant currency. Adjusted diluted earnings per share were $4.15. For fiscal 2026, revenue rose 4.9% to $19.5 billion, with adjusted earnings per share of $12.70. Cash from continuing operations climbed 30% to $3.6 billion, and free cash flow rose 42.5% to $2.9 billion. The medical technology company completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation on February 9, 2026. BD also plans to invest $19 billion in the US over several years, including $3 billion for manufacturing expansion. The agreement with the US government offers relief from future Section 232 tariffs on covered products. For fiscal 2027, BD expects low single-digit revenue growth and adjusted earnings per share of $13.10 to $13.30.